Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors
Harvard Bioscience (Nasdaq: HBIO) has announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. DeNelsky, who brings 30 years of healthcare industry experience, will serve on the Board's Nominating and Governance Committee.
Currently serving as Managing Director at Oaktree Capital Management, DeNelsky has extensive experience in research, analysis, and valuation of healthcare equities. He also serves on the board of Visioncare Inc and previously held board positions at Integrated Diagnostics and AMICAS, Inc. His expertise spans life sciences, pharmaceuticals, devices, and services sectors.
Harvard Bioscience (Nasdaq: HBIO) ha annunciato la nomina di Stephen DeNelsky nel proprio Consiglio di Amministrazione, con effetto dal 5 settembre 2025. DeNelsky, che vanta 30 anni di esperienza nel settore sanitario, entrerà a far parte del Comitato per le Nomine e la Corporate Governance del Consiglio.
Attualmente Managing Director presso Oaktree Capital Management, DeNelsky possiede una consolidata esperienza in ricerca, analisi e valutazione di titoli del settore sanitario. Siede inoltre nel consiglio di Visioncare Inc e ha precedentemente ricoperto incarichi nei board di Integrated Diagnostics e AMICAS, Inc. La sua competenza abbraccia scienze della vita, farmaceutica, dispositivi medici e servizi.
Harvard Bioscience (Nasdaq: HBIO) ha anunciado el nombramiento de Stephen DeNelsky en su Junta Directiva, con efecto a partir del 5 de septiembre de 2025. DeNelsky, que aporta 30 años de experiencia en la industria sanitaria, formará parte del Comité de Nominaciones y Gobernanza de la Junta.
Actualmente es Managing Director en Oaktree Capital Management, y cuenta con amplia experiencia en investigación, análisis y valoración de valores sanitarios. También forma parte del consejo de Visioncare Inc y anteriormente ocupó puestos en los directorios de Integrated Diagnostics y AMICAS, Inc. Su experiencia abarca ciencias de la vida, farmacéutica, dispositivos y servicios.
Harvard Bioscience (Nasdaq: HBIO)는 Stephen DeNelsky를 이사회에 선임한다고 발표했으며, 임명은 2025년 9월 5일부터 효력이 발생합니다. DeNelsky는 의료 산업 분야에서 30년의 경험을 보유하고 있으며 이사회의 지명 및 거버넌스 위원회에서 활동할 예정입니다.
현재 Oaktree Capital Management의 매니징 디렉터로 재직 중인 그는 의료 관련 주식의 조사, 분석 및 가치평가에 대한 폭넓은 경험을 가지고 있습니다. 또한 Visioncare Inc의 이사로 재직 중이며 이전에는 Integrated Diagnostics와 AMICAS, Inc.의 이사회에서도 활동했습니다. 그의 전문 분야는 생명과학, 제약, 의료기기 및 서비스에 걸쳐 있습니다.
Harvard Bioscience (Nasdaq: HBIO) a annoncé la nomination de Stephen DeNelsky au sein de son conseil d'administration, effective le 5 septembre 2025. DeNelsky, qui apporte 30 ans d'expérience dans le secteur de la santé, siègera au comité des nominations et de la gouvernance du conseil.
Actuellement Managing Director chez Oaktree Capital Management, DeNelsky possède une large expérience en recherche, analyse et valorisation d'actions du secteur de la santé. Il siège également au conseil d'administration de Visioncare Inc et a auparavant occupé des postes au sein des conseils d'Integrated Diagnostics et d'AMICAS, Inc. Son expertise couvre les sciences de la vie, la pharmacie, les dispositifs médicaux et les services.
Harvard Bioscience (Nasdaq: HBIO) hat die Ernennung von Stephen DeNelsky in den Vorstand bekannt gegeben, wirksam zum 5. September 2025. DeNelsky bringt 30 Jahre Erfahrung in der Gesundheitsbranche mit und wird dem Nominierungs- und Governance-Ausschuss des Vorstands angehören.
Als derzeitiger Managing Director bei Oaktree Capital Management verfügt DeNelsky über umfassende Erfahrung in der Recherche, Analyse und Bewertung von Gesundheitsaktien. Er ist außerdem Vorstandsmitglied von Visioncare Inc und war zuvor im Vorstand von Integrated Diagnostics und AMICAS, Inc. tätig. Sein Fachwissen erstreckt sich über Biowissenschaften, Pharma, Medizintechnik und Dienstleistungssektoren.
- None.
- None.
Veteran life sciences industry financing leader appointed as new Board member
HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board’s Nominating and Governance Committee.
“We are pleased to announce Steve as the newest member of our Board of Directors at such an important time for Harvard Bioscience,” said John Duke, President & CEO. “His knowledge across the verticals we operate in, as well as his expertise in guiding life sciences companies on financial strategy will be invaluable as we move forward.”
“I’m honored to join the Board and look forward to contributing to thoughtful governance and long-term value creation at Harvard Bioscience,” said Mr. DeNelsky.
Mr. DeNelsky possesses 30 years of experience in the research, analysis, and valuation of public and private equities in the healthcare industry. He currently serves as Managing Director at Oaktree Capital Management and has held senior roles at Marathon Asset Management and Life Sciences Alternative Funding. He has worked across all major sub-sectors of healthcare, including life sciences, pharmaceuticals, devices and services. Mr. DeNelsky also brings strong board experience and currently serves on the board of Visioncare Inc and previously served on the boards of Integrated Diagnostics and AMICAS, Inc. Mr. DeNelsky received a B.A. in Economics from the American University and an M.B.A. from the University of Maryland.
“We are thrilled that Steve has joined Harvard Bioscience’s Board and we are already benefiting from his extensive life sciences lending expertise” said Katherine Eade, Lead Independent Director.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenue and gross margin, and matters relating to the Company’s ability to continue as a going concern, fund its operations, or refinance outstanding indebtedness. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
(508) 893-3120
investors@harvardbioscience.com
FAQ
Who is Stephen DeNelsky and what is his new role at Harvard Bioscience (HBIO)?
What experience does Stephen DeNelsky bring to Harvard Bioscience's board?
What other board positions does Stephen DeNelsky hold?
What is Stephen DeNelsky's educational background?
